Inflammation in the Pathophysiology and Therapy of Cardiometabolic Disease

Area of Science:

• Endocrinology and Metabolism
• Immunology
• Pharmacology

Background:

• Chronic inflammation is integral to type 2 diabetes mellitus (T2DM) pathogenesis.
• Metabolic inflammation negatively impacts insulin secretion, action, and glucose homeostasis.
• T2DM complications are often linked to underlying inflammatory processes.

Purpose of the Study:

• To review the role of anti-inflammatory interventions in managing T2DM and metabolic syndrome.
• To evaluate the efficacy of existing and novel anti-inflammatory drugs in T2DM patients.
• To highlight the need for further clinical research into personalized anti-inflammatory treatment strategies for T2DM.

Main Methods:

• Review of current literature on inflammation in T2DM pathogenesis.
• Analysis of clinical trial data for anti-inflammatory drugs in metabolic syndrome.
• Focus on interleukin-1 (IL-1) antagonists and other anti-inflammatory agents.

Main Results:

• Therapeutic strategies targeting metabolic inflammation improve insulin sensitivity and glycemic control.
• IL-1 antagonists demonstrate benefits in beta-cell function, glycemia, and cardiovascular outcomes.
• Potential for alternative or combination anti-inflammatory treatments based on individual patient factors.

Conclusions:

• Anti-inflammatory drugs represent a promising therapeutic avenue for T2DM and metabolic syndrome.
• Personalized approaches considering genetic factors and disease characteristics are crucial for optimal treatment.
• Further comprehensive clinical studies are essential to integrate anti-inflammatory therapies into standard T2DM care.